
TINA.org Supports FTC’s ‘Click to Cancel’ Rule against Industry Challenge
Companies should not be able to trap consumers into subscriptions that they do not want.
Fust et al. v. Gilead Sciences, Inc.
23-at-1244, E.D. Cal.
(Sept. 2023)
Remdesivir
Falsely marketing Remdesivir as safe and effective against COVID-19 without disclosing its limitations and adverse events, including fatalities
Pending
Companies should not be able to trap consumers into subscriptions that they do not want.
Getting out may not be as easy as signing up.
Ellen Lee, The New York Times
TINA.org discovers the evidence behind these weight-loss claims is slim.
Watch out for hidden fees.